Accordingly, targeted pharmacological therapies, such as metreleptin for patients carrying biallelic LEP variants and setmelanotide for patients with biallelic LEPR, POMC, and PCSK1 variants, are available for selected monogenic obesity forms [5–7]. This evidence concerns the gene PCSK1 and Obesity.